BIAS
TGTX icon

Beacon Investment Advisory Services’s TG Therapeutics TGTX Stock Holding History

Beacon Investment Advisory Services’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,000
Closed -$150K – 288
2023
Q1 		$150K Buy
+10,000
New +$152K 0.01% 273

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Beacon Investment Advisory Services's TGTX Position: Q2 2023 in Review

Beacon Investment Advisory Services sold out of TG Therapeutics (TGTX) in Q2 2023, closing a stake of 10,000 shares — an estimated $150K sold.

Beacon Investment Advisory Services first reported a position in TGTX in Q1 2023 and held it in 1 quarter. The position peaked at $150K in Q1 2023. 244 funds tracked by Wall St. Rank hold TGTX as of Q2 2023.

  • Beacon Investment Advisory Services reported no remaining TG Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Beacon Investment Advisory Services sold 10,000 TG Therapeutics shares in Q2 2023, an estimated $150K.
  • Beacon Investment Advisory Services first reported a position in TG Therapeutics in Q1 2023 and held it in 1 quarter.
  • Beacon Investment Advisory Services's TG Therapeutics position peaked at $150K in Q1 2023.
  • 244 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2023.

Based on Beacon Investment Advisory Services's 13F filing for Q2 2023, filed 21 Jul 2023.